Zoetis (NYSE: ZTS) reported Q1 EPS of $1.26, $0.24 better than the analyst estimate of $1.02. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.73 billion.

• Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Quarter 2021
• Reports Adjusted Net Income of $603 Million, or Adjusted Diluted EPS of $1.26, for First Quarter 2021
• Delivers 21% Operational Growth in Revenue and 34% Operational Growth in Adjusted Net Income for First Quarter 2021

“We are off to a very strong start in 2021 -- our best quarter ever -- with 21% operational revenue growth and 34% growth in adjusted net income, as we continue to build on our innovative petcare portfolio, expand in key markets outside the U.S., and accelerate sales of diagnostics products,” said Kristin Peck, Chief Executive Officer of Zoetis.

“Looking ahead, we are raising guidance for operational growth in full-year revenue to the range of 10.5% to 12%. The fundamental growth drivers for our industry continue to show strong and sustainable momentum, and we remain confident that our diverse portfolio across species and geographies, our pipeline of innovative new products and lifecycle innovations, and the agility and commitment of our colleagues will continue driving our success in 2021 and beyond."

GUIDANCE:

Zoetis sees FY2021 EPS of $4.42-$4.51, versus the consensus of $4.45. Zoetis sees FY2021 revenue of $7.5-7.625 billion, versus the consensus of $7.47 billion.

For earnings history and earnings-related data on Zoetis (ZTS) click here.